Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Background/objective Disorders of Gut–Brain interactions (DGBI), for example, Functional Dyspepsia (FD) or Irritable Bowel syndrome (IBS), are common in patients with hypermobile EhlersDanlos syndrome/hypermobile spectrum disorder (hEDS/HSD). DGBI is associated with significant healthcare use—how this applies to patients with coexisting hEDS/HSD is unknown. Design A cross-sectional study was performed. Patients recruited from tertiary neurogastroenterology clinics and from EhlersDanlos Support UK completed questionnaires, characterising their demographic, healthcare data and expenses, over 6 months (July 2021–January 2022) and their Rome IV diagnoses. National Health Service (NHS) unit costs were used. Healthcare use and costs were compared across and between DGBI and non-DGBI subgroups. Regression analysis was performed to determine predictors of costs. p<0.005 was considered significant. Results Median age of the 660 respondents was 39 (IQR: 29–50) years; 96.1% had a DGBI. 13.6% had IBS, 29.9% had FD, 32.1% had IBS and FD, 24.4% had neither. Patients with DGBI had high healthcare use and large healthcare costs; £3388.79/6 months, mostly attributed to consultations (36.4%) and admissions (22.7%). Costs per patient (pp) were at least double in any group with FD (£4026.53– £4297.30pp) compared with those without (£1372.49–£1979.36pp), p<0.001. The highest costs were in FD patients (>£20 000 pp/6months). Predictors of rising costs were FD, non-gastrointestinal comorbidities, lower body mass index, positive avoidant/restrictive food intake disorders screen, having an altered diet, polypharmacy, visits to different healthcare professionals and tertiary neurogastroenterology recruitment. Conclusions It is imperative to develop cost-effective multidisciplinary services for hEDS/HSD patients with FD, particularly in the current fiscal climate, as they have significant healthcare use and costs.

Original publication

DOI

10.1136/flgastro-2025-103250

Type

Journal article

Journal

Frontline Gastroenterology

Publication Date

01/01/2025